ViralClear Publishes in F1000 Research In Vitro Data Demonstrating Synergy between Merimepodib and Remdesivir Against SARS-Co...
May 14 2020 - 8:15AM
- Merimepodib in combination with remdesivir decreases
viral production of SARS-CoV-2 to undetectable levels in
pre-clinical testing. Even at low concentrations of both
drugs significant reduction in viral production
occurs.
- Article highlights recent work done in laboratory
studies of COVID-19 with merimepodib at the Galveston National
Laboratory at The University of Texas Medical Branch
BioSig Technologies, Inc. (Nasdaq: BSGM) today announced that an
article titled, “The IMPDH inhibitor merimepodib provided in
combination with the adenosine analogue remdesivir reduces
SARS-CoV-2 replication to undetectable levels in vitro” was
published by F1000 Research, an online peer-reviewed life
sciences journal publishing program in biology and medicine, while
it is undergoing peer review.
This manuscript is authored by Natalya Bukreyeva, Rachel A.
Sattler, Emily K. Mantlo, Timothy Wanninger, John T. Manning, Cheng
Huang and Slobodan Paessler of the UTMB Galveston National
Laboratory and Dr. Jerome Zeldis of ViralClear Pharmaceuticals,
Inc. (“ViralClear”) as a corresponding author. The link to the
manuscript is https://f1000research.com/articles/9-361/v1.
The article highlights pre-clinical data generated under
contract with Galveston National Laboratory at The University of
Texas Medical Branch.
“The results of these laboratory investigations have strongly
influenced our plans for the initial clinical trials of
merimepodib. We have experimental evidence that merimepodib is
active as monotherapy and in combination with remdesivir,”
commented Jerome Zeldis, M.D., Ph.D, Executive Chair and
Co-Founder of ViralClear Pharmaceuticals, Inc. “Our first proposed
COVID-19 trial is expected to be conducted in hospitalized patients
who require supplemental oxygen and receive remdesivir as part of
their standard of care. Patients will be randomized to either
placebo or merimepodib. In this manner, the potential synergy
between merimepodib and remdesivir may be evaluated in the clinical
setting. An additional trial in the outpatient setting with
just merimepodib is proposed to follow the initiation of the first
trial.”
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE EP(tm) System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
About ViralClearBioSig’s subsidiary ViralClear
Pharmaceuticals, Inc., is seeking to develop a novel pharmaceutical
to treat advanced COVID-19.
Merimepodib is a broad-spectrum anti-viral agent that has
demonstrated strong activity against the SARS-CoV-2 virus in cell
cultures in laboratory testing. ViralClear plans to initiate a
multi-center, phase 2, randomized, double-blind, placebo-controlled
study of the efficacy and safety of merimepodib administered orally
three times a day for 10 days in combination with remdesivir
administered by intravenous infusion once a day for 5 or up to 10
days in adult patients with advanced COVID-19 upon FDA clearance to
proceed. Merimepodib has been studied in twelve clinical trials
prior to this planned study, including five trials in patients with
hepatitis C (one phase 1b, one phase 2, two phase 2a, and one phase
2b), one trial in patients with psoriasis (phase 2), and seven
trials in healthy volunteers (phase 1).
Remdesivir is an adenosine analogue that displays broad-spectrum
antiviral activity against RNA viruses and has been developed by
Gilead Pharmaceuticals for the treatment of Ebola. On May 1, 2020,
remdesivir received an FDA Emergency Use Authorization to treat
COVID-19 in adults and children hospitalized with severe
disease.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024